Non-alcoholic Fatty Liver Disease Clinical Trial
— SMASHOfficial title:
SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
NCT number | NCT02696941 |
Other study ID # | 11693 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | February 2016 |
Est. completion date | April 1, 2018 |
Verified date | May 2018 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
SGLT2 inhibitors have been proven to be effective in several preclinical rodent models of
non-alcoholic fatty liver disease (NAFLD). Using a choline deficient diet to recapitulate
some of the histological features of human non-alcoholic steatohepatitis (NASH), it was found
that 5 weeks of SGLT2 inhibition led to significant reductions in hepatic triglyceride
content and improved markers of liver fibrosis. Similarly, 4 weeks of treatment in obese mice
led to improved glucose tolerance, reduced hepatic steatosis and reduced markers of liver
oxidative stress in a dose dependent manner. These findings corresponded with an improvement
in traditional liver function tests including the aminotransferases (ALT and AST). The widely
used antidiabetic agent metformin has been shown in rodent models to increase hepatic insulin
sensitivity and lower liver fat content which is in contrast to the findings in humans where
metformin increases hepatic insulin sensitivity, reduces body weight but does not decrease
liver fat content. The reason for the discrepancy between the animal and human studies, with
regards to liver fat content remains unclear.
The investigators hypothesise the following:
- SGLT2 Inhibitors have the potential to decrease lipid accumulation in the liver through
reduced de novo lipogenesis (DNL)
- There will be no decrease in endogenous lipid synthesis (DNL) with metformin and thus no
change in liver fat content.
There are two arms to this study.
- Arm 1: x10 participants with poorly controlled type 2 Diabetes (T2DM) who have been
recommended to start an SGLT2 inhibitor called dapagliflozin will be recruited.
- Arm 2: x13 participants with insulin resistance who have not yet started any diabetic
medication will be recruited and will be prescribed metformin at standard clinical
doses.
The two arms will run in parallel and all participants will undergo identical investigations
before and after 3 months of treatment with either dapagliflozin or metformin. Investigations
will include liver magnetic resonance imaging/spectroscopy, fat biopsy, fat microdialysis
sampling, two-step hyperinsulinaemic euglycaemic clamp, breath sampling and stable glucose
and palmitate isotope infusions.
The investigators aim to show that SGLT2 inhibition decreases liver fat whereas we aim to
demonstrate why liver fat remains unchanged in humans, treated with metformin. These data
will provide the first evidence for the use SGLT2 inhibitors in NAFLD, and will be highly
informative for the design of future clinical studies. Moreover, the data gained from the
metformin arm of the study will provide the first mechanistic evidence in humans of the
effects of metformin on hepatic fatty acid metabolism.
Status | Completed |
Enrollment | 20 |
Est. completion date | April 1, 2018 |
Est. primary completion date | April 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: Arm 1: SGLT2 inhibitors - Volunteers with diagnosis of Type 2 Diabetes on oral anti-diabetic therapy at a stable dose for =3 months including one of the following: i. Metformin monotherapy ii. Sulphonylurea monotherapy iii. Metformin and Sulphonylurea dual therapy - All volunteers will be due to start SGLT2 inhibitor therapy for inadequate glycaemic control and it will be prescribed according to licensed indications. Arm 2: metformin • Insulin resistant treatment naive individuals as defined by fasting insulin and / or glucose in top 10th percentile Both arms: - Participant is willing and able to give informed consent for participation in the study. - Male or Female, aged between 18 years and 70 years. - BMI: 25-45 kg/m2 - HbA1C: 42-86mmol/mol - Normal renal function Exclusion Criteria: Arm 1: SGLT2 inhibitors Volunteers taking insulin, glucagon-like peptide 1 analogues, thiazolidinediones, or dipeptidyl peptidase IV inhibitors Arm 2: metformin Volunteers taking insulin, glucagon-like peptide 1 analogues, thiazolidinediones, SGLT2 inhibitors, metformin or dipeptidyl peptidase IV inhibitors Both arms - Age <18 or >70 years - Body mass index <25 or >45kg/m2 - A blood haemoglobin <120mg/dL - History of alcoholism or a greater than recommended alcohol intake (Recommendations > 21 drinks on average per week in men and > 14 drinks on average per week in women) - Pregnant or nursing mothers - History of severe claustrophobia - Presence of metallic implants, pacemaker - Haemorrhagic disorders - Anticoagulant treatment - History of albumin allergy |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Oxford | Oxford |
Lead Sponsor | Collaborator |
---|---|
University of Oxford |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hepatic steatosis | Liver fat measured by magnetic resonance imaging / spectroscopy (MRI/S) | 3 months | |
Secondary | % contribution of newly synthesised lipid to circulating triglyceride levels | deuterated water incorporation into palmitate | 3 months | |
Secondary | Global insulin sensitivity | two-step hyperinsulinaemic-euglycaemic clamp | 3 months | |
Secondary | Hepatic insulin sensitivity | two-step hyperinsulinaemic-euglycaemic clamp | 3 months | |
Secondary | Intrabdominal fat | Intrabdominal fat depot measured at level of L4-L5, visible on liver MRI. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |